An observational study in Cruciate Ligament Reconstruction Infection, Septic Arthritis and Surgical Wound Infection, sponsored by First Affiliated Hospital of Fujian Medical University. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by First Affiliated Hospital of Fujian Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This retrospective cohort study evaluates a sequential diagnostic strategy for patients with postoperative cruciate ligament reconstruction infection (CLRI). Diagnosing these infections is often difficult because conventional laboratory cultures can easily miss fastidious or slow-growing microorganisms. This study investigates whether using a rapid DNA-based test called metagenomic next-generation sequencing (mNGS) to guide and customize subsequent laboratory culture conditions can improve the detection rate of viable, live pathogens. The study includes 50 patients with CLRI and 30 patients with aseptic failure (non-infectious complications). The ultimate goal is to determine if this mNGS-guided modified culture strategy can help doctors identify the exact infection-causing germs more accurately, thereby allowing them to provide targeted, individualized antibiotic and surgical treatments.
English Version :
This is a retrospective, single-center cohort study evaluating patients evaluated for suspected postoperative cruciate ligament reconstruction infection (CLRI) between January 2015 and January 2026. The study enrolled 50 patients who were clinically diagnosed with CLRI and 30 comparator patients who underwent revision surgery for aseptic failure (AF). Study Protocol:
Pre-therapy synovial fluid was aspirated under sterile conditions and divided into at least three aliquots. Conventional Culture: The first aliquot was processed immediately using routine aerobic and anaerobic microbiological culture methods (incubated for up to 7-14 days). mNGS Testing: The second aliquot was transported immediately for metagenomic next-generation sequencing (mNGS) testing to quickly identify potential microbial nucleic acids. mNGS-Guided Modified Culture: The third aliquot was preserved at -80°C. Once the mNGS result became available (within 48 hours), a clinical microbiologist reviewed the detected microorganisms and prescribed individualized modifications to the subsequent culture protocol for the preserved aliquot. These modifications were tailored to the suspected pathogen's biological characteristics and included the use of specialized culture media (e.g., Sabouraud dextrose agar, Mycobacteria Growth Indicator Tube systems), prolonged incubation, strictly anaerobic conditions, and supplementary identification procedures. Objectives and Assessments:
The primary objective is to compare the diagnostic yield (positive detection rates of viable pathogens) among pre-therapy conventional culture, pre-therapy mNGS, and the sequential mNGS-guided modified culture strategy. The study also evaluates how this enhanced, actionable microbiological information informs individualized clinical management. Specifically, it assesses treatment decision-making algorithms-integrating pathogen characteristics, infection duration, and graft/fixation mechanical stability-to determine the feasibility of non-operative antimicrobial management or graft-preserving surgical options such as debridement, antibiotics, and implant retention (DAIR).
51 studies on the registry are indexed under Arthritis, Infectious; 12 are open to participants now.
This study's enrollment of 80 is below the median of 100 across 30 observational studies indexed under Arthritis, Infectious.
Browse Arthritis, Infectious studies →First Affiliated Hospital of Fujian Medical University is the lead sponsor of 97 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of patients who were evaluated and treated for suspected postoperative cruciate ligament reconstruction infection (CLRI) or who underwent revision surgery for aseptic failure (AF) at a single tertiary referral center (The First Affiliated Hospital of Fujian Medical University) between January 2015 and January 2026. This includes both patients treated primarily at this center and those referred from other hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinically diagnosed cruciate ligament reconstruction infection (CLRI) or patients who underwent revision surgery for aseptic failure (AF).
Preoperative joint aspiration performed at our institution.
Adequate preoperative samples available for concurrent microbial culture and metagenomic next-generation sequencing (mNGS) testing.
Complete clinical and laboratory data.
Exclusion Criteria:
Specimen contamination (e.g., specimens clearly contaminated during collection or processing, or microorganisms isolated from only a single culture that did not align with the clinical judgement of the expert team).
Concomitant systemic inflammatory disease or that could interfere with laboratory test results.
Long-term use of drugs or .
Missing key clinical data.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients clinically diagnosed with postoperative cruciate ligament reconstruction infection (CLRI) who underwent preoperative joint aspiration.
Diagnostic Test: Metagenomic next-generation sequencing (mNGS) · Diagnostic Test: mNGS-guided modified culture · Diagnostic Test: Conventional microbiological culture
Comparator patients undergoing revision surgery for aseptic failure (AF), defined by the absence of clinical, laboratory, imaging, and microbiological evidence of infection.
Diagnostic Test: Metagenomic next-generation sequencing (mNGS) · Diagnostic Test: mNGS-guided modified culture · Diagnostic Test: Conventional microbiological culture
Pre-therapy synovial fluid was analyzed by mNGS to rapidly detect microbial nucleic acids and identify potential pathogens.
A subsequent synovial fluid culture protocol customized based on pre-therapy mNGS results, utilizing specialized media, prolonged incubation, or specific atmospheric conditions to improve viable pathogen recovery.
Routine aerobic and anaerobic microbiological culture methods used as the standard baseline test.
Pathogen Detection Rate
The percentage of patients in whom potential or viable microorganisms were successfully detected from pre-therapy synovial fluid. This measure compares the diagnostic yield among pre-therapy conventional culture, pre-therapy metagenomic next-generation sequencing (mNGS), and the mNGS-guided modified culture strategy.
Time frame: Up to 14 days after synovial fluid aspiration (based on the maximum culture incubation period).
Rate of Clinical Infection Control (Treatment Success)
The percentage of patients achieving successful infection management and clinical infection control, defined according to the consensus criteria of the Musculoskeletal Infection Society (MSIS). This evaluates the clinical outcome after individualized antimicrobial and surgical management.
Time frame: At the last follow-up (minimum 6 months after discharge).
Plan to share: Yes — The datasets analysed during the current study are not publicly available because they contain information that could compromise patient privacy, but are available from the corresponding author on reasonable request.
Supporting information: Analytic code
No publications or documents are linked to this record.
Ran from Jan 2015 to primary completion in Jan 2026, 132 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Fujian Medical University